(INCY) Incyte - Ratings and Ratios
Cancer Treatments, Blood Disorders, Skin Conditions, Leukemia Therapies
INCY EPS (Earnings per Share)
INCY Revenue
Description: INCY Incyte
Incyte Corporation is a biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics across various regions including the United States, Europe, Canada, and Japan. The companys product portfolio includes several key drugs targeting various conditions such as myelofibrosis, polycythemia vera, graft-versus-host disease, diffuse large B-cell lymphoma, and atopic dermatitis, among others.
The companys commercial success is driven by its marketed products, including JAKAFI, MONJUVI/MINJUVI, PEMAZYRE, ICLUSIG, ZYNYZ, NIKTIMVO, and OPZELURA, which have shown significant potential in treating various cancers and immune disorders. With a diverse pipeline of clinical-stage products, Incyte is also exploring new therapeutic areas, including ovarian cancer, solid tumors, hidradenitis suppurativa, and fibrodysplasia ossificans progressiva.
From a financial perspective, Incytes market capitalization stands at approximately $13.3 billion, indicating a significant presence in the biotechnology sector. The companys price-to-earnings ratio is around 327, while the forward P/E is substantially lower at 11.81, suggesting potential for earnings growth. Return on Equity (ROE) is 0.64, which may indicate room for improvement in terms of profitability. Key Performance Indicators (KPIs) to watch include revenue growth from its marketed products, the progression of its clinical-stage pipeline, and the companys ability to expand its market share in the competitive biotech industry.
To further evaluate Incytes potential, its essential to monitor its research and development (R&D) expenses, as a significant portion of its expenditures are allocated towards advancing its pipeline products. The companys collaboration with Genesis Therapeutics, Inc. also highlights its commitment to exploring new therapeutic opportunities. As the biotech landscape continues to evolve, Incytes ability to innovate and bring new treatments to market will be crucial in driving its long-term success.
INCY Stock Overview
| Market Cap in USD | 16,981m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1993-11-04 |
INCY Stock Ratings
| Growth Rating | 8.53% |
| Fundamental | 68.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 7.70% |
| Analyst Rating | 3.67 of 5 |
INCY Dividends
Currently no dividends paidINCY Growth Ratios
| Growth Correlation 3m | 87.4% |
| Growth Correlation 12m | 18.3% |
| Growth Correlation 5y | -56.9% |
| CAGR 5y | 8.34% |
| CAGR/Max DD 3y | 0.21 |
| CAGR/Mean DD 3y | 0.35 |
| Sharpe Ratio 12m | 1.43 |
| Alpha | 0.02 |
| Beta | 0.961 |
| Volatility | 29.68% |
| Current Volume | 1582.5k |
| Average Volume 20d | 1688.5k |
| Stop Loss | 82.2 (-3.1%) |
| Signal | 0.41 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (870.9m TTM) > 0 and > 6% of Revenue (6% = 275.1m TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA 6.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 51.58% (prev 31.89%; Δ 19.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 1.00b > Net Income 870.9m (YES >=105%, WARN >=100%) |
| Net Debt (-1.91b) to EBITDA (1.36b) ratio: -1.41 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (198.5m) change vs 12m ago -9.01% (target <= -2.0% for YES) |
| Gross Margin 92.88% (prev 92.64%; Δ 0.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 87.47% (prev 82.74%; Δ 4.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 516.9 (EBITDA TTM 1.36b / Interest Expense TTM 2.45m) >= 6 (WARN >= 3) |
Altman Z'' 3.69
| (A) 0.41 = (Total Current Assets 3.64b - Total Current Liabilities 1.28b) / Total Assets 5.82b |
| (B) -0.09 = Retained Earnings (Balance) -509.7m / Total Assets 5.82b |
| (C) 0.24 = EBIT TTM 1.26b / Avg Total Assets 5.24b |
| (D) -0.30 = Book Value of Equity -496.0m / Total Liabilities 1.65b |
| Total Rating: 3.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.94
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 6.33% = 3.16 |
| 3. FCF Margin 20.62% = 5.16 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda 0.28 = 2.44 |
| 6. ROIC - WACC (= -5.74)% = -7.17 |
| 7. RoE 24.09% = 2.01 |
| 8. Rev. Trend 86.20% = 6.46 |
| 9. EPS Trend 17.56% = 0.88 |
What is the price of INCY shares?
Over the past week, the price has changed by -1.68%, over one month by -0.14%, over three months by +23.24% and over the past year by +27.65%.
Is Incyte a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INCY is around 80.25 USD . This means that INCY is currently overvalued and has a potential downside of -5.37%.
Is INCY a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 15
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the INCY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.7 | -3.7% |
| Analysts Target Price | 81.7 | -3.7% |
| ValueRay Target Price | 90.2 | 6.3% |
Last update: 2025-09-04 10:00
INCY Fundamental Data Overview
CCE Cash And Equivalents = 2.42b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 20.5579
P/E Forward = 12.6103
P/S = 3.7036
P/B = 4.0714
P/EG = 0.1297
Beta = 0.716
Revenue TTM = 4.58b USD
EBIT TTM = 1.26b USD
EBITDA TTM = 1.36b USD
Long Term Debt = 371.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 10.6m USD (from shortTermDebt, last quarter)
Debt = 382.5m USD (Calculated: Short Term 10.6m + Long Term 371.8m)
Net Debt = -1.91b USD (from netDebt column, last quarter)
Enterprise Value = 14.94b USD (16.98b + Debt 382.5m - CCE 2.42b)
Interest Coverage Ratio = 516.9 (Ebit TTM 1.26b / Interest Expense TTM 2.45m)
FCF Yield = 6.33% (FCF TTM 945.6m / Enterprise Value 14.94b)
FCF Margin = 20.62% (FCF TTM 945.6m / Revenue TTM 4.58b)
Net Margin = 18.99% (Net Income TTM 870.9m / Revenue TTM 4.58b)
Gross Margin = 92.88% ((Revenue TTM 4.58b - Cost of Revenue TTM 326.5m) / Revenue TTM)
Tobins Q-Ratio = -30.12 (set to none) (Enterprise Value 14.94b / Book Value Of Equity -496.0m)
Interest Expense / Debt = 0.16% (Interest Expense 594.0k / Debt 382.5m)
Taxrate = 89.70% (284.0m / 316.6m)
NOPAT = 130.3m (EBIT 1.26b * (1 - 89.70%))
Current Ratio = 2.85 (Total Current Assets 3.64b / Total Current Liabilities 1.28b)
Debt / Equity = 0.09 (Debt 382.5m / last Quarter total Stockholder Equity 4.17b)
Debt / EBITDA = 0.28 (Net Debt -1.91b / EBITDA 1.36b)
Debt / FCF = 0.40 (Debt 382.5m / FCF TTM 945.6m)
Total Stockholder Equity = 3.61b (last 4 quarters mean)
RoA = 14.96% (Net Income 870.9m, Total Assets 5.82b )
RoE = 24.09% (Net Income TTM 870.9m / Total Stockholder Equity 3.61b)
RoCE = 31.73% (Ebit 1.26b / (Equity 3.61b + L.T.Debt 371.8m))
RoIC = 3.60% (NOPAT 130.3m / Invested Capital 3.61b)
WACC = 9.34% (E(16.98b)/V(17.36b) * Re(9.55%)) + (D(382.5m)/V(17.36b) * Rd(0.16%) * (1-Tc(0.90)))
Shares Correlation 3-Years: -27.27 | Cagr: -1.10%
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 65.94% ; FCFE base≈747.0m ; Y1≈531.0m ; Y5≈284.7m
Fair Price DCF = 22.04 (DCF Value 4.30b / Shares Outstanding 195.3m; 5y FCF grow -33.99% → 3.0% )
EPS Correlation: 17.56 | EPS CAGR: 41.88% | SUE: 0.65 | # QB: 0
Revenue Correlation: 86.20 | Revenue CAGR: 15.22% | SUE: 1.59 | # QB: 2
Additional Sources for INCY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle